MK-0524A

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Heterozygous Familial HypercholesterolemiaHypercholesteremiaHypercholesterolemia, FamilialHyperlipidemiaMixed DyslipidemiaMixed HyperlipidemiaPrimary Hypercholesterolemia

Phase 1

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

TerminatedNCT01583647

Merck Sharp & Dohme LLCHeterozygous Familial Hypercholesterolemia, Hypercholesterolemia, Familial

Start: 2012-06-30End: 2012-12-31Updated: 2015-11-03

Phase 3

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

CompletedNCT00289900

Merck Sharp & Dohme LLCMixed Hyperlipidemia

Start: 2006-01-24End: 2010-08-06Updated: 2018-08-31

Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)

CompletedNCT00376584

Merck Sharp & Dohme LLCHypercholesteremia, Hyperlipidemia

Start: 2006-07-31End: 2007-01-31Updated: 2017-02-16

MK-0524B Lipid Study (MK-0524B-063)

CompletedNCT00479882

Merck Sharp & Dohme LLCMixed Dyslipidemia, Primary Hypercholesterolemia

Start: 2007-06-15End: 2008-06-16Updated: 2019-02-06